Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neurogen (NRGN) -- Ignore unavailable to you. Want to Upgrade?

To: Doc Bones who wrote (379)	12/2/2003 7:25:51 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 523

<<It occurred to me that MRK might have the best chance of productive partnerships with small biotechs. They would be a more simpatico partner for a biotech than a PFE or similar behemoths.>> Merck is usually entering bios-alliance when they are confident on target/candidates based on internal projects. In NRHG case it is interesting that Merck had very strong VR-1 program on it’s own, still they saw great value in NRGN IP position and candidates potential. One way this alliance is conformation of the VR-1 as target. Hope program will now move faster and increase gap between them and competitors. Normally, it is way too early to project any success possibility, but I do hope that this is start of the new page in NRGN history. Miljenko